# Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis

> **NCT05204173** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer Stage IV
- Peritoneal Metastases

## Interventions

- **DRUG:** sintilimab, paclitaxel and S-1

## Key facts

- **NCT ID:** NCT05204173
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-20
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05204173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05204173, "Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05204173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*